VERSION 1 -REVIEW
DESIGN NEW DIAGNOSTIC SYSTEMS FOR THE EARLY DETECTION OF TOBACCO-ASSOCIATED CHRONIC RENAL DAMAGE is clearly written and well conducted.
Minor corrections: 1. Section introduction, Page 6, row 44 For the statement: "To study whether certain predisposition markers previously identified in our group (Ganglioside GM2 activator protein (GM2AP), transferrin, and t-Gelsolin).." corresponding reference(s) should be provided.
2. d should be replaced by D in the name of N-acetyl-beta-dglucosaminidase 3 . Section, Subjects of study, page 8, row 23: It is written: "A follow-up of 200 smoking patients recruited in the previous objective will be carried out, specifically 100 each from groups 1 and 3." Patients from group 1 are non-smoker? Section General variables, page 9, row 27, write biochemical parameters instead of "analytical biochemistry"
REVIEWER
Hung-Yi Chuang, MD, ScD Kaohsiung Medical University REVIEW RETURNED 06-Nov-2019 GENERAL COMMENTS This research protocol will investigate the kidney function damaged by tobacco uses. 1. Detecting subclinical renal damage in smokers using a panel of early biomarkers (albuminuria, NAG, KIM-1, and NGAL): they we hypothesize that tobacco consumption can predispose smokers to renal damage on exposure to other potentially nephrotoxic events, (pharmacological treatments, diagnostic procedures etc.). 2. Investigating whether certain predisposition markers (GM2AP, Transferrin, and t-Gelsolin) are able to detect smokers who are predisposed to kidney damage. 3. Studying whether smoking cessation reduces subclinical and/or predisposition to renal damage. Study design Four groups of patients: non-smoker without predisposed factors, non-smoker with predisposed factors, smoker without predisposed factors, smoker with predisposed factors. A total of 500 patients will be recruited (125 per group), which was calculated by statistical theory. For subjects 2 and 3, a longitudinal design will be proposed. The study began on March 4, 2019. The collection of samples will end in April 2022. The study will be completed in July 2022. The followup period will be 24 months.
Questions: 1. Authors should argue the reasoning why 24 months following is enough? 2. For kidney functions, why do they pick these biomarkers? Are these markers better than glomerular filtration rate? 3. What do the biomarkers, such as ganglioside GM2 activator protein (GM2AP), transferrin, and t-Gelsolin, react or inter-react with microalbumin and the enzyme N-acetyl-beta-dglucosaminidase (NAG), protein kidney damage molecule 1 (KIM-1), lipocalin associated with neutrophil gelatinase (NGAL)?
4. How can the protocol provide more information than those studies before, for example, 'The Multiple Risk Factor Intervention Trial' (MRFIT), 'Prevention of Renal and Vascular Endstage Disease' (PREVEND)? 5. It is better if authors could offer their budge estimating.
Zhen Wang Mayo Clinic, USA REVIEW RETURNED 06-Nov-2019
GENERAL COMMENTS
This manuscript is a study protocol of assessing early markers for subclinical renal damage in smokers. Three subsequent studies were proposed to address three objectives. I have the following comments and suggestions. 1. Please add diagnostic and prognostic information of the proposed markers in chronic renal diseases with or without tobacco use. 2. Please describe the rationale/theatrical reasoning that these early markers would work in renal damage caused by tobacco. In other words, why the makers evaluated in chronic renal diseases in other study would work differently in patients with tobacco use. 3. Table 1 , please clarify the meaning of "-". Also for "risk factors", X means patients have all of these risk factors, and "-" mean no risk factors at all? 5. Please add citation or background information about the numbers generated for sample size calculation in the sentence, "detect a minimum difference of 18 mg/g of the albumin/creatinine index between two of the four groups, considering a common standard deviation of 40 mg/g." 6. Subjects, please add more information on how patients will be sampled and recruited. Please add details on how to ensure no difference between groups on gender and age. 7. The STROBE statement is a reporting guideline, not a method guideline. Please delete the relevant sentences in the limitations. SPAIN) . Therefore, the objective of this paper is to design a protocol to be carried out with the appropriate methodology.
VERSION 1 -AUTHOR RESPONSE

REVIEWERS RESPONSE
In the section "METHODS AND ANALYSIS" are described the characteristics of the patients that will be recruited for the study. It must be considered that all the results will not be available until the end of the project. After that, the findings will be published.
Reviewer: 2 Reviewer Name: Gurjot Kaur Institution and Country: School of Pharmaceutical Sciences, Shoolini University, Solan, India Please state any competing interests or state 'None declared': none declared Please leave your comments for the authors below I really liked the study protocol except for few minor comments listed below: 1. How do you control for the diet changes that may affect your sample population as it is already reported that some components of our diet can affect renal health?
Indeed, the diet affects kidney function to patients who have previous alterations in renal function (Hershey, 2018; Riccio et al., 2015; Rysz et al., 2017) . In this work, patients with impaired renal function at the recruitment time will not be included. Therefore, control of dietary changes is not considered in this protocol. Minor corrections: 1. Section introduction, Page 6, row 44 For the statement: "To study whether certain predisposition markers previously identified in our group (Ganglioside GM2 activator protein (GM2AP), transferrin, and t-Gelsolin).." corresponding reference(s) should be provided.
References
References have been added in the place indicated by the reviewer. The sentence states as it follows: "(Objective 2) To study whether certain predisposition markers previously identified in our group (Ganglioside GM2 activator protein (GM2AP), transferrin, and t-Gelsolin), [17] [18] [19] [20] can detect those smokers who are predisposed to acute kidney injury".
d should be replaced by D in the name of N-acetyl-beta-d-glucosaminidase
"N-acetyl-beta-d-glucosaminidase" has been replaced by "N-acetyl-beta-D-glucosaminidase" throughout the entire manuscript.
3. Section, Subjects of study, page 8, row 23: It is written: "A follow-up of 200 smoking patients recruited in the previous objective will be carried out, specifically 100 each from groups 1 and 3." Patients from group 1 are non-smoker?
The mistake has been corrected. The current sentence is as follows: "A follow-up of 200 smoking patients recruited in the previous objective will be carried out, specifically 100 each from groups 1 and 3".
Section General variables, page 9, row 27, write biochemical parameters instead of "analytical biochemistry" "Analytical biochemistry" has been replaced by "biochemical parameters". Four groups of patients: non-smoker without predisposed factors, non-smoker with predisposed factors, smoker without predisposed factors, smoker with predisposed factors. A total of 500 patients will be recruited (125 per group), which was calculated by statistical theory. For subjects 2 and 3, a longitudinal design will be proposed. The study began on March 4, 2019. The collection of samples will end in April 2022. The study will be completed in July 2022. The follow-up period will be 24 months.
Questions: 1. Authors should argue the reasoning why 24 months following is enough?
The follow-up of the patients is considered a proof of concept to see the evolution of the markers since each patient has an individual history of smoking in terms of time and consumption. The choice of 24 months can be a reasonable time to obtain a first data of orientation. Depending on the results obtained, the follow-up time could be extended.
2. For kidney functions, why do they pick these biomarkers? Are these markers better than glomerular filtration rate?
The markers that we are going to evaluate appear earlier than the glomerular filtration rate decline, and hence they are better for detecting early or subclinical kidney damage. Precisely our hypothesis is that these markers can detect incipient kidney damage that would never be detected by the glomerular filtration rate or plasma creatinine. This is reflected in the Introduction of the manuscript, in the following paragraph:
"It is recognized that the key to preventive success is very early diagnosis, allowing intervention while the renal functional reserve has not yet been exhausted and, therefore, the excretory function is not yet compromised. [11] In the clinic, one of the most common diagnostic tools for kidney damage is the detection of metabolic products (for example creatinine and urea), which accumulate in the blood once the renal excretory capacity begins to decrease. However, at the stage when serum urea and creatinine levels are detectably increased, more than 70% of renal function has already been lost. Thus, there is a current trend in diagnostics to identify sensitive, specific, and easily quantifiable markers that detect incipient pathophysiological events in the early stages, when the damage is less widespread.
[12] These potential markers may, for example, be involved in the synthesis, activation, or inhibition of biochemical process mediators and cellular structural constituents related to processes such as apoptosis and tissue regeneration. Likewise, signs of destruction of tissues (extracellular matrix, and basal membranes) could be found in the urine, whether they are whole or degraded molecules, or remnants of organelles, cells, or tissues. The urinary detection of certain cellular enzymes associated with renal cell injury is currently the procedure for the early detection of the tubular subtype of kidney damage. In this sense, urinary detection of the enzyme N-acetyl-beta- 3. What do the biomarkers, such as ganglioside GM2 activator protein (GM2AP), transferrin, and t-Gelsolin, react or inter-react with microalbumin and the enzyme N-acetyl-beta-d-glucosaminidase (NAG), protein kidney damage molecule 1 (KIM-1), lipocalin associated with neutrophil gelatinase (NGAL)?
Each of these markers are independent of each other, providing different information about the damaged renal region and the altered mechanism. (Alfredo G. Casanova et al.,2020; Ferreira et al., Information regarding the recruitment of patients has been added to clarify this point. Specifically, the modified paragraph is as follows:
"Patients of legal age from the "La Alamedilla" Health Center of Salamanca (Spain) will be included. A total of 500 patients will be recruited (125 per group) at the general practitioner consult until reaching the estimated sample size. During the recruitment process we will ensure that there are no significant differences in terms of gender and age between the groups. To that purpose, while the recruitment is done, statistical studies will be conducted to ensure that the groups are homogeneous in terms of gender and age. Thus, the subsequent recruitment can be directed to have homogeneous groups".
7. The STROBE statement is a reporting guideline, not a method guideline. Please delete the relevant sentences in the limitations.
Everything related to the STROBE statement in the "Study Limitations" section has been removed VERSION 2 -REVIEW REVIEWER Hung-Yi Chuang, MD, ScD Kaohsiung Medical University, Taiwan REVIEW RETURNED 10-Dec-2019
GENERAL COMMENTS
I have no more comments.
